BioSpace News Archive

New research reported at the Alzheimer’s Association International Conference® 2023 covered the breadth of Alzheimer’s disease and dementia research, including advancements in treatment, early and accurate diagnosis, and our understanding of risk factors for Alzheimer’s and other dementias.

Promontory Therapeutics Inc. has expanded its clinical presence to France.

Avail Medsystems, the digital hub of the operating room (OR) enabling the MedTech and healthcare industries to work smarter together to advance patient care, today announced it will participate as a platinum partner in the Society of Robotic Surgery (SRS) Annual Meeting to be held July 24-26, 2023 in Melbourne, Australia.

GeneCentric Therapeutics announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp.

Imperative Care Announces Multiple Poster Presentations on the Zoom Stroke Solution at the Society of NeuroInterventional Surgery 20th Annual Meeting.

Sangamo Therapeutics, Inc. today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition.

Cleave Therapeutics, Inc. today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open.

BD, a leading global medical technology company, issued its Fiscal Year 2022 Environmental, Social and Governance Report that details ongoing efforts that impact company health, human health, community health and planet health.

Eliem Therapeutics, Inc. announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.